POLYPHOR AG Spexis announces business update call to be held on July 28th
Transparency directive : regulatory news
|
Spexis AG
/ Key word(s): Conference
Allschwil, Switzerland, July 20, 2022 Spexis announces business update call to be held on July 28th
Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET.
To participate, please use the following numbers:
France: +33 (0)1 70 730 3 39 Germany: +49 (0)69 22222 5197 Italy: +39 0200638217 Switzerland: +41 (0)44 580 7279 United Kingdom +44 (0)330 165 4012 United States +1 646-828-8075
Please dial in approximately 10 minutes prior to the start of the call. When asked, please provide the name of the event – “Spexis AG - Business and Strategy Update” – and the following confirmation code: 1507661.
The presentation will also be available via webcast:
A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.
For further information, please contact:
About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com. Disclaimer
End of Media Release |
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | info@spexisbio.com |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1405487 |
| End of News | EQS News Service |
|
|
1405487 25.07.2022